Editorial Commentary: Colistin and a New Paradigm in Drug Development

Clin Infect Dis. 2016 Mar 1;62(5):559-60. doi: 10.1093/cid/civ968. Epub 2015 Nov 25.

Authors

Françoise Van Bambeke¹, Paul M Tulkens¹

Affiliation

¹ Pharmacologie cellulaire et moléculaire and Centre of Clinical Pharmacy, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.

PMID: 26607423
DOI: 10.1093/cid/civ968

No abstract available

Keywords: EMA; FDA; breakpoints; colistin; dosage recommendations.

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Colistin*
Drug Resistance, Multiple, Bacterial / drug effects*
Humans
Microbial Sensitivity Tests

Substances

Anti-Bacterial Agents
Colistin